Closing the Gaps in NSCLC

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
Sponsored by

Episodes 0-0 of 0

Adjuvant Treatment of Early Non–Small Cell Lung Cancer in the Era of Immunotherapy

Heather Wakelee, MD, FASCO

Adjuvant Treatment of Early Non–Small Cell Lung Cancer in the Era of Immunotherapy

Learn More

Adjuvant Treatment of Early Non–Small Cell Lung Cancer in the Era of Immunotherapy

Host
Heather Wakelee, MD, FASCO

UP NEXT...

Key Strategies to Maintain Breast Health Amid the COVID-19 Pandemic

Guest
Ann L. Steiner, MD